For most patients on home bilevel therapy, a fixed or auto-titrating BiPAP is enough. For a meaningful minority — patients with obesity hypoventilation syndrome, neuromuscular disease, and central or mixed hypoventilation pictures — the device needs to guarantee a minimum tidal volume on each breath, not just a minimum pressure. That is what Target Volume Assured Pressure Support (TVAPS) does. Clinically, it is the bridge between BiPAP-ST and volume-cycled mechanical ventilation, and it is an increasingly common prescription in Indian home-ventilation practice.
This article covers the mechanism of TVAPS, its clinical indications, how a titration actually works, and what the Indian device landscape looks like in 2026 with pricing.
Mechanism — volume-targeted bilevel in detail
A standard BiPAP delivers two pressures: an IPAP on inspiration and an EPAP on expiration. The patient’s tidal volume on each breath is whatever the combination of pressure support (IPAP − EPAP), airway resistance, and respiratory compliance produces. In a stable patient this works fine. In a patient whose respiratory mechanics change through the night — worsening compliance during REM, shifting body position, changing upper-airway patency, progressive muscle fatigue — the tidal volume can fall below the threshold at which CO₂ clearance is adequate.
TVAPS addresses this by adding a volume target. The clinician sets:
- Target tidal volume (V_T target): typically 6–8 mL/kg ideal body weight, adjusted for the clinical picture. A 70 kg IBW patient targets 420–560 mL.
- Minimum and maximum IPAP: the pressure range within which the device is permitted to vary IPAP to achieve the target.
- EPAP: fixed or auto-EPAP within a range, for upper-airway splinting.
- Backup rate: breaths per minute delivered if the patient does not trigger.
- Rise time, cycle sensitivity, inspiratory time constraints: shape the breath.
On each breath, the device measures the delivered tidal volume (by integrating the flow signal over the inspiratory time) and compares it to the target. If the delivered volume is below target, IPAP increases on the next breath by a small increment. If above target, IPAP decreases. The adjustment is slow enough to remain comfortable (typical ramp is 1–2 cmH₂O per minute) and automatic enough to hold V_T stable through the night.
The therapeutic intent: maintain alveolar ventilation — and therefore CO₂ clearance — at a pre-set level regardless of changing mechanics. For a patient who retains CO₂ during REM or in the lateral position, TVAPS levels out the overnight CO₂ profile and reduces morning hypercapnia, sleep fragmentation, and daytime somnolence.
The trade name varies by manufacturer. Philips calls it AVAPS (Average Volume Assured Pressure Support). ResMed calls it iVAPS (intelligent VAPS). BMC and some generic brands call it TVAPS or simply VAPS. The underlying principle is the same across implementations, with manufacturer-specific differences in the algorithm’s response curves, smoothing, and rise-time handling.
The IPAP-ceiling question
The maximum IPAP setting is not a trivial parameter. Set it too low and the device cannot reach target volume in the worst part of the night — the patient hypoventilates during REM and wakes hypercapnic. Set it too high and the device, trying to compensate for a leak or a transient airway obstruction, can push pressure to uncomfortable levels and trigger arousals.
Practical IPAP max ceilings for TVAPS:
- OHS without bulbar involvement: 25–28 cmH₂O upper limit. Most OHS patients tolerate this range on full-face masks.
- NMD with intact bulbar function: 20–25 cmH₂O, reassessed with disease progression.
- Nasal pillows interface: 20 cmH₂O max is a practical leak ceiling regardless of the underlying indication.
- Pediatric patients: lower ceilings, indication-specific. Requires pediatric sleep specialist.
Rise time
Rise time — how fast the machine reaches IPAP from EPAP at the start of each breath — matters more in TVAPS than in standard BiPAP. A patient with NMD who fatigues wants a fast rise time (100–200 ms) so the machine is doing the work. A patient with OHS and a tolerant ventilatory picture may prefer a slower rise (300–600 ms) for comfort. Titration often starts at 300 ms and adjusts based on patient report and objective ventilation data.
Clinical indications
TVAPS is not first-line for sleep-disordered breathing. It is the right tool for a specific set of clinical pictures:
Obesity hypoventilation syndrome (OHS)
OHS is defined as obesity (BMI ≥ 30) with chronic daytime hypercapnia (PaCO₂ ≥ 45 mmHg) not explained by other conditions. Many OHS patients have coexistent OSA, and CPAP is often tried first. Those whose daytime CO₂ does not normalise on CPAP — roughly half in published series — benefit from TVAPS. The volume target ensures adequate nocturnal ventilation even as obese chest wall mechanics change with posture and sleep stage. (Masa JF et al, Pickwick trial (Lancet 2019))
The Pickwick trial is the strongest evidence for TVAPS (specifically AVAPS in that study) in OHS: long-term nocturnal non-invasive ventilation was non-inferior to CPAP for most hard endpoints in OHS patients with concurrent severe OSA, and superior to CPAP for normalisation of daytime CO₂ in OHS without concurrent severe OSA. The practical implication: if OHS is present and CO₂ does not normalise on CPAP at adequate adherence over 3 months, step up to TVAPS.
Neuromuscular disease
Progressive respiratory muscle weakness in ALS, muscular dystrophies (Duchenne, Becker, limb-girdle), post-polio syndrome, and similar conditions produces a clinical picture where the patient cannot reliably generate an adequate tidal volume on a fixed pressure support. As the disease progresses, more pressure support is needed to move the same volume. TVAPS auto-escalates the support without requiring repeated clinical titration visits.
For ALS specifically, home non-invasive ventilation is a standard of care from the point of documented respiratory muscle weakness (FVC < 50% predicted for non-bulbar disease, earlier for bulbar-predominant presentation), and TVAPS-capable BiPAPs are the standard prescribed devices in centres with access. (ATS/ERS statement) In bulbar-predominant ALS, the patient may not tolerate nasal interfaces due to secretion management concerns; TVAPS is still clinically appropriate but the interface decision is harder.
Central hypoventilation
Congenital central hypoventilation syndrome, acquired central hypoventilation (brainstem lesions from stroke or surgery), and some variants of primary alveolar hypoventilation all require assured ventilation overnight. A backup rate alone (BiPAP-ST) sets a minimum rate but not a minimum volume; TVAPS sets both. For patients with central hypoventilation of significant severity, TVAPS is usually preferred over BiPAP-ST.
COPD with chronic hypercapnia
A specific subset: stable severe COPD with persistent daytime hypercapnia (PaCO₂ > 50 mmHg) and a history of recurrent hypercapnic exacerbations. Long-term home NIV — often with a volume-assurance component — reduces readmission and mortality in this population. (Murphy PB et al, JAMA 2017) Not all COPD patients benefit; patient selection is a specialist decision. Some centres use BiPAP-ST rather than TVAPS for this indication and report similar outcomes; the evidence base supports both.
Kyphoscoliosis and restrictive chest wall disease
Similar mechanics to neuromuscular disease — reduced chest wall compliance makes a fixed pressure support produce variable volumes. TVAPS holds the volume stable.
How TVAPS differs from BiPAP-ST
| Feature | BiPAP-ST | TVAPS (AVAPS / iVAPS) |
|---|---|---|
| Pressures | Fixed IPAP and EPAP | IPAP varies within a set min–max window; EPAP fixed or auto |
| Targets | Pressure only | Tidal volume (primary); pressure (bounded) |
| Breath delivery | Spontaneous + backup rate | Spontaneous + backup rate (same) |
| Control variable | Pressure | Volume (pressure as manipulated variable) |
| Response to changing mechanics | Tidal volume varies with mechanics | Tidal volume held constant; pressure varies |
| Set-up complexity | Moderate | Higher — requires V_T target calculation, min/max pressure selection, sensitivity tuning |
| Typical indication | Stable OSA-overlap, moderate NMD | OHS, progressive NMD, central hypoventilation, chronic hypercapnic COPD |
In practice, TVAPS-capable machines retain a straight BiPAP-ST mode, and the clinician switches modes based on the clinical target. A patient can be initiated on BiPAP-ST, trialed, and stepped up to TVAPS if overnight oximetry or transcutaneous CO₂ shows inadequate ventilation on S/T alone.
TVAPS-capable devices in the Indian market
A representative but non-exhaustive list of devices with volume-assurance capability available in India in 2026, with typical pricing. Prices vary by distributor, region, and whether humidifier and heated tubing are bundled.
| Device | Trade name for VAPS | Pressure range | Typical price (INR) | Notes |
|---|---|---|---|---|
| ResMed Lumis VPAP ST-A (with iVAPS) | iVAPS | 4–30 cmH₂O | 2,20,000–3,00,000 | Mature algorithm, strong AirView cloud ecosystem, preferred for NMD progression tracking |
| ResMed Lumis 150 VPAP | iVAPS | 4–30 cmH₂O | 2,40,000–3,00,000 | Higher-end Lumis variant with enhanced data reporting |
| Philips DreamStation BiPAP AVAPS | AVAPS | 4–25 cmH₂O | 2,00,000–2,50,000 | Widely prescribed in Indian OHS and NMD populations, SD-card data download |
| Home Medix HM-BV-30 | TVAPS | 4–30 cmH₂O | 1,40,000–1,60,000 | Regional availability; verify service network in your location |
| BMC G3 B30VT | VAPS | 4–30 cmH₂O | 1,50,000–1,80,000 | Budget-leaning, extensive Indian distribution, algorithm less validated in peer-reviewed literature |
The pricing spread reflects ecosystem and clinical-validation differences more than feature presence. ResMed and Philips have a larger base of published validation studies; BMC and other brands are established in Indian practice but rely more on manufacturer white papers than independent peer-reviewed work. Device selection is a clinical decision and should weigh service-network availability at the patient’s location — a machine that requires return-to-Bengaluru-or-Mumbai for every fault creates real therapy-interruption risk at the patient end. For NMD progression in particular, where a patient may go from BiPAP-S to BiPAP-ST to TVAPS to full home ventilator over a few years, ecosystem continuity (same manufacturer, same cloud reporting, same service network) is a material advantage.
Titration basics — what a respiratory therapist looks for
Titration of TVAPS is more involved than CPAP or standard BiPAP titration:
- Set the target tidal volume. Typically 6–8 mL/kg ideal body weight. A 70 kg IBW patient targets 420–560 mL. Too low and ventilation is inadequate; too high and the patient either overventilates (causing reflex apnea that triggers the backup rate) or experiences leak-inducing pressures.
- Set the IPAP range. Minimum IPAP is typically 2–4 cmH₂O above EPAP to provide adequate pressure-support baseline. Maximum IPAP is set at a level the patient tolerates and the interface can hold without excessive leak — usually 25–28 cmH₂O on a nasal or full-face mask, lower on a nasal pillow.
- Set EPAP. Enough to keep the upper airway open if OSA coexists — typically 5–10 cmH₂O. Some devices allow auto-EPAP within a range.
- Set backup rate. 12–16 breaths per minute is typical for OHS and stable NMD; higher (16–20) for advanced NMD and some central hypoventilation pictures.
- Set rise time and I-time constraints to shape the breath — faster rise for NMD patients who fatigue, longer I-time for patients with compromised gas exchange.
- Verify overnight. Oximetry alone is insufficient; transcutaneous CO₂ monitoring (tcCO₂) or morning blood gas is the reference for whether the titration was correct.
- Track adherence and events on follow-up. A TVAPS titration is rarely final on the first attempt. Follow-ups at 1 month, 3 months, and 6 months adjust target V_T and pressure limits as the clinical picture evolves.
A well-done TVAPS titration normalises morning CO₂, produces stable overnight SpO₂, and shows a distribution of delivered IPAP across the target range (not pinned at the minimum, which suggests target is too low, or pinned at the maximum, which suggests target is too high or the interface is leaking).
A practical note on Indian prescribing
TVAPS prescriptions in India are concentrated in a handful of specialist centres. For a patient buying in a location without easy access to a sleep lab or a home-ventilation service, the setup challenge is real. A well-run prescription path typically involves:
- Sleep study at a reference centre, with full respiratory montage including tcCO₂ where available.
- In-lab NIV titration with CO₂ monitoring — this is the step most commonly skipped in the Indian context, and the skipping is the root cause of most unsatisfactory TVAPS therapy.
- Device procurement from a distributor who can service it locally.
- A home-respiratory-therapist visit to confirm setup.
- A physician review at 30 days with overnight oximetry or tcCO₂ data.
Short-cutting any of these steps tends to produce a patient who owns a device that is incorrectly titrated and who, therefore, is not getting the clinical benefit the mode is capable of providing. Families paying out of pocket for a ₹1.5–3.0 lakh device deserve to have the titration done correctly; pushing distributors and clinicians for a proper titration visit is not an unreasonable ask.
The bottom line
TVAPS is the right mode for a defined set of clinical pictures — OHS with CPAP-non-responsive hypercapnia, progressive neuromuscular disease, central hypoventilation, selected chronic hypercapnic COPD, and restrictive chest wall disease. It is not a comfort upgrade over BiPAP-S or BiPAP-ST; it is a therapeutic step reserved for patients whose underlying problem is inadequate alveolar ventilation rather than upper-airway collapse. Device selection should weigh algorithm maturity, ecosystem continuity, and local service availability. Titration quality matters more than device brand in determining clinical outcome.
Consult your pulmonologist or sleep physician for TVAPS prescription and titration.
References: AASM and ATS guidance on NIV for hypoventilation; Masa et al (Pickwick); Murphy et al, Thorax 2012 and JAMA 2017; Köhnlein et al; Bourke et al; ATS/ERS statement on NIV in neuromuscular disease; individual device manufacturer clinical and technical white papers [CITATION].